Safety Study of TPI-287 to Treat CBS and PSP

NCT02133846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Primary Four Repeat Tauopathies (4RT)
Corticobasal Syndrome (CBS)
Progressive Supranuclear Palsy (PSP)
Corticobasal Degeneration (CBD)

Interventions

DRUG: TPI 287 2 mg/m2
DRUG: TPI-287 20 mg/m2
DRUG: Placebo
DRUG: TPI-287 6.3 mg/m2

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]